Adcetris Plus AVD Promising in Newly Diagnosed Hodgkin's Patients

A small phase I study suggests that adding Adcetris to AVD chemotherapy and removing the radiation aspect could be just as effective in treating newly diagnosed Hodgkin's patient.

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center, and colleagues, carried out a phase I, single-arm, open label, dose-escalation trial among patients with stage II to stage IV newly diagnosed Hodgkin lymphoma would benefit from receiving Adcetris (brentuximab vedotin) the antibody-drug conjugate containing an anti-CD30 monoclonal antibody, in combination with either ABVD or AVD. They wanted to know whether combining the antibody-drug conjugate with the standard of care might reduce the number of chemotherapy cycles needed to be effective as a treatment for this patient population.

They recruited 51 patients. Results indicate that in the Adcetris plus ABVD arm, 95 percent of patient achieved complete remissions, and in the Adcetris plus AVD arm, 96 percent of patients achieved complete remission.

Removing the radiation aspect from standard treatment appeared to be of no consequence when Adcetris was added to chemotherapy, leading researchers to begin a phase III trial of Adcetris plus AVD in newly diagnosed Hodgkin's patients.

This could spare future patients the longterm side effect of receiving radiation therapy.

The major drawback from the study was that nearly half the patients in the Adcetris plus ABVD arm experienced serious lung toxicities.

Their findings were published in the journal Lancet Oncology.

Source: OncLive

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...